Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Kemurnian >98,0% (GC) Lenvatinib Mesylate Intermediate Factory
Pasokan Kimia Ruifu Lenvatinib Mesylate Intermediates Kanthi Kemurnian Dhuwur
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Metil 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimetil-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Jeneng Kimia | Metil 4-Amino-2-Methoxybenzoate |
sinonim | 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Metil 4-Amino-o-Anisate;4-Amino-o-Anisic Asam Metil Ester |
Nomer CAS | 27492-84-8 |
Nomer CAT | RF-PI1974 |
Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
Formula Molekul | C9H11NO3 |
Bobot Molekul | 181.19 |
Kapadhetan | 1,179±0,060 g/cm3 |
Merk | Kimia Ruifu |
Item | Spesifikasi |
Penampilan | Putih nganti Bubuk Putih utawa Kristal |
Kemurnian / Metode Analisis | > 98,0% (GC) |
Kemurnian / Metode Analisis | 97.5~102.5 (Titrasi Nonnaqueous) |
Titik Lebur | 157.0~161.0 ℃ |
Mundhut ing Pangatusan | <1.00% |
Total Impurities | <2.0% |
Spektrum Infra Merah | Conforms kanggo Struktur |
Proton NMR Spectrum | Conforms kanggo Struktur |
Test Standar | Standar Perusahaan |
Panggunaan | Penengah saka Lenvatinib Mesylate (CAS: 857890-39-2) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) bisa digunakake minangka perantara saka Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib minangka obat kanker tiroid sing dikembangake dening Eisai Corporation of Japan (Kode: E7080), sing kalebu inhibitor multi-reseptor tyrosine kinase (RTK) lisan lan bisa nyandhet aktivitas kinase saka faktor pertumbuhan endothelial vaskular (VEGF) Reseptor VEGFR1 ( FLT1), VEGFR2 (KDR), lan VEGFR3 (FLT4).Lenvatinib uga bisa nyandhet keterlibatan RTK liyane ing angiogenesis patologis, pertumbuhan tumor, lan perkembangan kanker kajaba fungsi seluler normal kalebu reseptor faktor pertumbuhan fibroblast (FGF) FGFR1, 2, 3, lan 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, lan RET.[Indikasi]: Lenvatinib cocok kanggo perawatan pasien kanker tiroid saka jinis kambuh utawa metastasis lokal, jinis progresif lan jinis diferensiasi yodium-refraktori radioaktif.Tanggal 13 Februari 2015, FDA AS nyetujoni obat antikanker Lenvatinib kanggo perawatan kanker tiroid.Lenvatinib minangka inhibitor enzim multi-target, sing bisa nyandhet VEGFR2 lan VEGFR3 (reseptor faktor pertumbuhan endothelial vaskular).Jeneng dagang Lenvatinib yaiku Lenvima.Ing Mei 20, 2015, European Medicines Agency (EMA) nyetujoni Lenvatinib kanggo perawatan kanker tiroid (DTC) invasif, maju sacara lokal utawa metastatik (papillary, follicular, Hurthle type).Ing uji coba, wektu urip rata-rata kanggo pasien DTC radioaktif yodium-refractory sing diobati karo Lenvatinib yaiku 18 sasi, dene nilai kanggo pasien sing njupuk plasebo mung 3 wulan.